Gasporox (GPX) Q4 2024 earnings summary

Executive summary

• Revenue for Q4 2024 was 8,007 KSEK, up from 7,403 KSEK in Q4 2023; full-year revenue reached 34,104 KSEK, a 9% increase year-over-year.

• Operating loss for Q4 was -1,085 KSEK (vs. -835 KSEK last year); full-year operating loss was -2,183 KSEK (vs. -576 KSEK).

• Cash flow for Q4 was -1,611 KSEK; cash at year-end was 6,813 KSEK.

• No dividend proposed for the year.

• Company continues to expand globally, with a strong position in pharmaceutical and food packaging quality control.

Financial highlights

• Q4 revenue: 8,007 KSEK (Q4 2023: 7,403 KSEK); full-year: 34,104 KSEK (2023: 31,428 KSEK).

• Q4 operating result: -1,085 KSEK (Q4 2023: -835 KSEK); full-year: -2,183 KSEK (2023: -576 KSEK).

• Q4 cash flow: -1,611 KSEK; full-year: -3,808 KSEK.

• Year-end cash: 6,813 KSEK (2023: 10,621 KSEK); equity ratio: 67% (2023: 53%).

• EPS for Q4: -0.12 SEK (Q4 2023: -0.10 SEK); full-year: -0.30 SEK (2023: -0.14 SEK).

Outlook and guidance

• Focus remains on expanding in pharmaceuticals, food, and beverage markets, with continued product innovation and global reach.

• Management expects continued growth, driven by new product launches and increased demand for non-destructive quality control.

• No further capital needs anticipated to reach positive cash flow, barring major strategic changes.